28/06/2019  0:00:00 Diferencia - Volumen Bid- Ask- Capitalización de mecado Dividendo A. P/E Ratio
245.60EUR - 0
Volumen de negocios: 0.00
-Volumen de oferta: - -Tamaño/ Volumen/ Formato de Ask: - 215.08 mil millonesEUR - -

Descripción de negocio

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
 

Consejo de gestión & Consejo de supervisión

CEO
Dr. Thomas Schinecker
Consejo de gestión
Dr. Alan Hippe, Cristina A. Wilbur, Teresa Graham, Matt Sause , Claudia Bockstiegel, Prof. Dr. Hans Clevers, Dr. Levi Garraway, Silke Hornstein, Dr. Aviv Regev, Dr. James H. Sabry, Barbara Schadler
Consejo de supervisión
André Hoffmann, Anita Hauser, Bernard Poussot, Dr. Claudia Süssmuth Dyckerhoff, Dr. Patrick Frost, Dr. Severin Schwan, Prof. Dr. Richard Lifton, Dr. Mark Schneider, Dr. Jemilah Mahmood, Prof. Dr. Akiko Iwasaki, Dr. Joorg Duschmale
 

Datos de la empresa

Nombre: Roche Holding
Dirección: Grenzacherstraße 124,CH-4070 Basel
Teléfono: +41-61-688-1111
Fax: -
E-mail: basel.webmaster@roche.com
Internet: www.roche.com
Industria: Healthcare
Sector: Pharmaceutical Industry
Subsector: Pharmaceuticals
Fin del año financiero: 31/12
Acciones de libre circulación: 88.00%
Fecha de OPI: 03/04/1995

Relación con inversores

Nombre: Bruno Eschli
IR teléfono: +41 (61) 687 5284
IR-fax: +41 (61) 691 0014
IR e-mail: investor.relations@roche.com

Calendario de la empresa

CW 30 | 25/07/2024 Interim Report 2nd Quarter/6 Months
CW 43 | 23/10/2024 Interim Report 3rd Quarter/9 Months
 

Accionistas mayoritarios

Aktionärsgruppe der Familien Hoffmann und Oeri-Hoffmann
 
67.50%
Freefloat
 
24.92%
Maja Oeri
 
7.58%